Choo Andrew Y, Broderick Kate E, Kim Joseph J, Sardesai Niranjan Y
Inovio Pharmaceuticals, 1787 Sentry Parkway West, Building 18, Suite 400, Blue Bell, PA 19422, USA.
IDrugs. 2010 Oct;13(10):707-12.
The recent outbreaks of the H5N1 and H1N1 pandemic influenza have highlighted the importance of developing fast, effective therapeutic strategies to prevent and/or limit the spread of future influenza outbreaks. Although current vaccines against influenza are generally effective, several limitations, including those associated with the amount of available vaccine, the time to vaccine production and vaccine efficacy, may encumber a mass vaccination strategy and effective targeting against future outbreaks. This feature review discusses the prospects of SynCon-derived DNA vaccines against influenza; such vaccines are expected to be effective at targeting many currently circulating influenza virus strains, as well as potentially targeting strains that may be associated with future outbreaks. Because of advantages associated with safety, time to production and ease of production, as well as the generation of more effective immune responses, influenza DNA vaccines provide a promising potential solution to a global medical concern.
近期H5N1和H1N1大流行性流感的爆发凸显了制定快速、有效治疗策略以预防和/或限制未来流感爆发传播的重要性。尽管目前的流感疫苗总体上是有效的，但包括与可用疫苗数量、疫苗生产时间和疫苗效力相关的一些局限性，可能会阻碍大规模疫苗接种策略以及针对未来爆发的有效靶向。这篇专题综述讨论了基于合成构建体（SynCon）的流感DNA疫苗的前景；此类疫苗有望有效针对许多当前正在传播的流感病毒株，以及可能针对与未来爆发相关的毒株。由于在安全性、生产时间和生产便利性方面具有优势，以及能产生更有效的免疫反应，流感DNA疫苗为全球医疗问题提供了一个有前景的潜在解决方案。
